HeraMED Completes HeraBEAT trial with “excellent” results
- Pregnancy technology company HeraMED (HMD) completes the Hera BEAT clinical trial with Israel’s Sheba Medical Center which achieved “excellent” results
- A total of 10 patients were recruited in the study and went through an observation telemedicine visit using Hera BEAT
- The trial measured the patients’ first in-person visit compared to the telemedicine encounter with a 60 per cent reduction in the online meeting
- The platform allows expecting mothers to monitor their foetus’ heartbeat anytime, anywhere and share data with medical professionals
- The platform ends the day in the grey with shares trading at 12 cents
